Company Overview
IO Biotech, Inc. operates as a clinical-stage biopharmaceutical company dedicated to developing immune-modulating therapeutic cancer vaccines derived from its proprietary T-win technology platform. The company's lead therapeutic candidate, specifically the IO102-IO103 formulation, is engineered to target both cancer cells and immune-suppressive cells within the tumor microenvironment. This entity functions within the broader Healthcare sector and the specialized Biotechnology industry, positioning itself to leverage advancements in oncology research and immunotherapy. As of the latest reporting period, the company maintains a market capitalization of $13.89 million while employing a workforce of 80 individuals to drive its research and development initiatives. The combination of a relatively small market cap and the absence of reported annual revenue indicates that IO Biotech, Inc. is currently in a pre-commercialization phase where capital allocation is heavily weighted toward clinical trials and platform development rather than generating sales-based returns.
Financial Health
The financial statements for IO Biotech, Inc. reflect a typical profile for a clinical-stage biotechnology firm with reported revenue of N/A and a net income (TTM) of $-88,349,000. The company also reports an EBITDA of $-91,802,000, revealing a significant operational gap where expenses substantially exceed any revenue generation, a dynamic common in early-stage asset development but indicative of high burn rates. Free cash flow stands at $-49,063,376, which signifies that the company is utilizing its cash reserves to fund operations and research rather than returning capital to shareholders or generating liquidity. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a valuation characteristic of companies with no current sales volume where traditional profitability ratios are not applicable. Despite the negative earnings, the company holds $30.66 million in cash against $18.12 million in debt, resulting in a debt-to-equity ratio of 1988.91 that reflects a highly leveraged balance sheet structure relative to its equity base. Liquidity is supported by a current ratio of 2.01, suggesting the company possesses sufficient current assets to cover its short-term obligations without immediate distress. Return on Equity is reported at -240.5% and Return on Assets at -88.6%, metrics that illustrate how management is currently sacrificing profitability to advance clinical candidates rather than optimizing shareholder returns from existing operations.
Valuation Assessment
Valuation metrics for IO Biotech, Inc. present a complex picture due to the lack of traditional earnings data, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -0.52. The negative forward P/E implies that analysts or market models are projecting future earnings that would theoretically result in a negative multiple, though this is often an artifact of negative current earnings in the biotechnology sector rather than a standard valuation signal. The price-to-book ratio is 14.85, indicating that the market values the company's equity at a significant premium above its net asset book value, a scenario driven by the potential value of intangible assets like intellectual property and clinical data. Alternative valuation measures such as Price to Sales (N/A) and EV/EBITDA (-0.01) further complicate the assessment, with the EV/EBITDA suggesting the enterprise value is negligible relative to earnings, a common feature when earnings are deeply negative. The stock has demonstrated extreme volatility over the last year, trading between a 52-Week High of $2.79 and a 52-Week Low of $0.14. Given the 52-week low of $0.14 and high of $2.79, the current trading environment represents a significant distance from the yearly peak, reflecting the speculative nature of the asset. The beta value is 0.44, which indicates that the stock's price movements are less volatile than the broader market, moving with lower sensitivity to general market fluctuations despite the high inherent risk of the clinical development stage.
Growth & Income
Growth metrics for IO Biotech, Inc. show Revenue Growth (YoY) and Earnings Growth (YoY) as N/A, reflecting the company's current stage where historical growth rates are not yet established by commercial sales. In the absence of positive earnings, the distinction between revenue and earnings growth is moot, as the company is focused on achieving product milestones rather than expanding profit margins or sales volume. Regarding income generation, the company does not pay a dividend, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%. This 0.0% payout ratio is entirely consistent with a net income of $-88,349,000, as a negative earnings base makes dividend distribution impossible, meaning any future earnings will likely be reinvested into R&D. Consequently, the overall growth and income profile of IO Biotech, Inc. is characterized by a complete reliance on external capital and cash reserves to fund future expansion, with no current mechanism for providing income to investors through dividends or earnings growth.